Dr. Alka Rao becomes first woman director of CSIR-IMTECH

Accomplished molecular microbiologist and protein engineer takes charge of CSIR-IMTECH after serving in key scientific and regulatory leadership roles at FSSAI

Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial

The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)

Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial

The therapy also delivered significant improvements in key liver enzyme markers

Fermenta Biotech reports 26% revenue growth in FY26

EMA backs conditional EU nod for Vijoice in rare life-threatening overgrowth disorder PROS

The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments

US FDA okays Merck's new once-daily HIV pill

The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir

Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%

The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints

NADMED forms global Scientific Advisory Board to advance redox diagnostics and precision medicine

The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways

Apollo report warns India’s silent health risks are striking earlier among young adults

Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals